Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
412.23
-2.45 (-0.59%)
At close: Aug 25, 2025, 4:00 PM
417.10
+4.87 (1.18%)
After-hours: Aug 25, 2025, 7:46 PM EDT
Madrigal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts that cover Madrigal Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $445.71, which forecasts a 8.12% increase in the stock price over the next year. The lowest target is $350 and the highest is $523.
Price Target: $445.71 (+8.12%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Madrigal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 3 | 5 | 5 | 5 | 5 |
| Buy | 6 | 4 | 4 | 4 | 4 | 2 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 9 | 10 | 10 | 10 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Maintains $483 → $485 | Buy | Maintains | $483 → $485 | +17.65% | Aug 20, 2025 |
| UBS | UBS | Strong Buy Maintains $458 → $523 | Strong Buy | Maintains | $458 → $523 | +26.87% | Aug 12, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $420 → $428 | Strong Buy | Maintains | $420 → $428 | +3.83% | Aug 6, 2025 |
| UBS | UBS | Strong Buy Maintains $441 → $458 | Strong Buy | Maintains | $441 → $458 | +11.10% | May 2, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Reiterates $422 → $460 | Strong Buy | Reiterates | $422 → $460 | +11.59% | May 2, 2025 |
Financial Forecast
Revenue This Year
696.52M
from 180.13M
Increased by 286.67%
Revenue Next Year
1.17B
from 696.52M
Increased by 67.98%
EPS This Year
-13.54
from -21.90
EPS Next Year
0.65
from -13.54
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 827.8M | 1.6B | 2.2B | ||
| Avg | 696.5M | 1.2B | 1.8B | ||
| Low | 587.5M | 862.7M | 1.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 359.5% | 123.5% | 88.0% | ||
| Avg | 286.7% | 68.0% | 54.7% | ||
| Low | 226.1% | 23.9% | -1.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -7.18 | 20.31 | 36.67 | ||
| Avg | -13.54 | 0.65 | 18.79 | ||
| Low | -19.54 | -12.23 | -1.95 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 5,562.8% | ||
| Avg | - | - | 2,801.2% | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.